Entero Therapeutics (ENTO) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 12, 2020
Cover [Abstract]
Entity Registrant Name	AzurRx BioPharma, Inc.
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Entity Central Index Key	0001604191
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		28,502,850
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity File Number	001-37853
Entity Current Reporting Status	Yes
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 984,950	$ 175,796
Other receivables	102,601	2,637,303
Prepaid expenses	321,299	595,187
Deferring offering costs	192,071	0
Total Current Assets	1,600,921	3,408,286
Property, equipment, and leasehold improvements, net	62,054	77,391
Other Assets:
Patents, net	3,143,310	3,407,084
Goodwill	1,889,879	1,886,686
Operating lease right-of-use assets	129,553	82,386
Deposits	36,071	41,047
Total Other Assets	5,198,813	5,417,203
Total Assets	6,861,788	8,902,880
Current Liabilities:
Accounts payable and accrued expenses	1,314,281	1,754,682
Accounts payable and accrued expenses - related party	396,853	533,428
Notes payable	112,609	444,364
Convertible debt	5,285,340	1,076,938
Other current liabilities	506,526	476,224
Total Current Liabilities	7,615,609	4,285,636
Other liabilities	43,629	0
Total Liabilities	7,659,238	4,285,636
Stockholders' Equity:
Common stock - Par value $0.0001 per share; 150,000,000 shares authorized; 28,502,850 and 26,800,519 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.	2,850	2,680
Additional paid in capital	73,124,380	68,575,851
Accumulated deficit	(72,651,900)	(62,694,732)
Accumulated other comprehensive loss	(1,272,780)	(1,266,555)
Total Stockholders' Equity	(797,450)	4,617,244
Total Liabilities and Stockholders' Equity	$ 6,861,788	$ 8,902,880

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock shares, par value	$ .0001	$ 0.0001
Common stock shares, authorized	150,000,000	150,000,000
Common stock shares, issued	28,502,850	26,800,519
Common stock shares, outstanding	28,502,850	26,800,519

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Research and development expenses	$ 1,089,177	$ 2,875,851	$ 2,642,537	$ 6,172,146
General and administrative expenses	1,304,527	2,056,340	2,679,618	3,363,688
Loss from operations	(2,393,704)	(4,932,191)	(5,322,155)	(9,535,834)
Other:
Interest expense	(2,302,174)	(110,646)	(4,635,013)	(167,757)
Total other	(2,302,174)	(110,646)	(4,635,013)	(167,757)
Loss before income taxes	(4,695,878)	(5,042,837)	(9,957,168)	(9,703,591)
Income taxes	0	0	0	0
Net loss	(4,695,878)	(5,042,837)	(9,957,168)	(9,703,591)
Other comprehensive loss:
Foreign currency translation adjustment	(163,719)	26,488	(6,225)	(68,793)
Total comprehensive loss	$ (4,859,597)	$ (5,016,349)	$ (9,963,393)	$ (9,772,384)
Basic and diluted weighted average shares outstanding	28,016,478	20,479,917	27,479,140	19,107,534
Loss per share - basic and diluted	$ (0.17)	$ (0.25)	$ (0.36)	$ (0.51)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance, shares at Dec. 31, 2018	17,704,925
Beginning balance, amount at Dec. 31, 2018	$ 1,771	$ 5,139,259	$ (47,517,046)	$ (1,150,112)	$ 4,473,872
Common stock issued from public offering, shares	2,522,097
Common stock issued from public offering, amount	$ 252	5,023,704			5,023,956
Common stock issued to consultants, shares	40,481
Common stock issued to consultants, amount	$ 4	89,996			90,000
Common stock issued for warrant exercises, shares	775,931
Common stock issued for warrant exercises, amount	$ 77	1,740,882			1,740,959
Stock-based compensation		511,335			511,335
Restricted stock granted to employees/directors,, shares	60,000
Restricted stock granted to employees/directors, amount	$ 6	493,448			493,454
Convertible debt converted into common stock, amount		325,320			325,320
Warrant modification		61,590			61,590
Received from stockholder in relation to warrant modification					61,590
Foreign currency translation adjustment				(68,793)	(68,793)
Net loss			(9,703,591)		(9,703,591)
Ending balance, shares at Jun. 30, 2019	21,103,434
Ending balance, amount at Jun. 30, 2019	$ 2,110	61,385,534	(57,220,637)	(1,218,905)	2,948,102
Beginning balance, shares at Dec. 31, 2019	26,800,519
Beginning balance, amount at Dec. 31, 2019	$ 2,680	68,575,851	(62,694,732)	(1,266,555)	4,617,244
Common stock issued to settle accounts payable, shares	105,937
Common stock issued to settle accounts payable, amount	$ 11	131,126			131,137
Common stock issued to consultants, shares	101,195
Common stock issued to consultants, amount	$ 10	87,095			87,105
Common stock issued to Lincoln Park for Equity Purchase Agreement, shares	1,495,199
Common stock issued to Lincoln Park for Equity Purchase Agreement, amount	$ 149	988,199			988,348
Warrants issued in association with convertible debt issuances		1,252,558			1,252,558
Beneficial conversion feature on convertible debt issuances		1,838,422			1,838,422
Stock-based compensation		251,129			251,129
Received from stockholder in relation to warrant modification					0
Foreign currency translation adjustment				(6,225)	(6,225)
Net loss			(9,957,168)		(9,957,168)
Ending balance, shares at Jun. 30, 2020	28,502,850
Ending balance, amount at Jun. 30, 2020	$ 2,850	$ 73,124,380	$ (72,651,900)	$ (1,272,780)	$ (797,450)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (9,957,168)	$ (9,703,591)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	18,368	34,041
Amortization	263,774	693,176
Non-cash lease expense	(6,065)	0
Common stock issued to settle accounts payable	131,137	0
Stock-based compensation	230,126	511,335
Restricted stock granted to employees/directors	21,003	493,454
Common stock granted to consultants	87,105	90,000
Accreted interest on convertible debt	319,196	74,521
Accretion of debt discount	4,203,182	87,959
Changes in assets and liabilities, net of effects of acquisition:
Accounts receivables	(36,033)	0
Other receivables	2,548,659	(193,152)
Prepaid expenses	274,019	312,672
Right of use assets	(108,447)	(240,993)
Deposits	5,000	(4,125)
Accounts payable and accrued expenses	(571,728)	940,347
Deferred offering costs	(192,071)	0
Other liabilities	135,210	250,579
Net cash used in operating activities	(2,634,733)	(6,653,777)
Cash flows from investing activities:
Purchase of property and equipment	(2,808)	(13,337)
Net cash used in investing activities	(2,808)	(13,337)
Cash flows from financing activities:
Proceeds from issuance of notes payable, net	179,418	0
Proceeds issuances of common stock, net	988,348	5,023,956
Proceeds issuances of convertible debt, net	3,227,002	2,000,000
Received from stockholder in relation to warrant modification	0	61,590
Repayments of convertible debt	(450,000)	0
Repayments of notes payable	(511,173)	(190,318)
Net cash provided by financing activities	3,433,595	6,895,228
Increase in cash	796,054	228,114
Effect of exchange rate changes on cash	13,100	(31,770)
Cash, beginning balance	175,796	1,114,343
Cash, ending balance	984,950	1,310,687
Supplemental disclosures of cash flow information:
Cash paid for interest	104,153	5,277
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Common stock issued for patents purchased from Mayoly	0	1,740,959
Warrant modification related to convertible debt issuance	$ 0	$ 325,320

The Company and Basis of Presen

The Company and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	Description of Business AzurRx BioPharma, Inc. (“ AzurRx Parent ProteaBio Europe SAS ABS Company The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Non-systemic biologics are non-absorbable drugs that act locally, i.e. the intestinal lumen, skin or mucosa, without reaching an individual’s systemic circulation. The Company is currently focused on developing its lead drug candidate, MS1819, EPI CF CP Yarrowia lipolytica The Company is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial in the U.S. and Europe, and the Combination therapy trial in Europe, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. Recent Developments Series B Private Placement and Exchange On July 16, 2020 (the “ Series B Closing Date Series B Private Placement Series B Purchase Agreement Series B Investors Series B Preferred Stock Common Stock Series B Warrants In connection with the Private Placement, an aggregate of 1,975.578900 shares of Series B Preferred Stock initially convertible into 19,755,795 shares of Common Stock and related 7,379,790 Series B Warrants were issued for cash consideration, resulting in aggregate gross proceeds of approximately $15.2 million and aggregate net proceeds to the Company of approximately $13.5 million after deducting placement agent compensation and expenses. In addition, the balance of an aggregate of 937.004221 shares of Series B Preferred Stock initially convertible into 9,370,039 shares of Common Stock and related Series B Warrants to purchase 4,685,040 shares of Common Stock was issued to certain Series B Investors (the “ Exchange Investors Promissory Notes Exchange Exchange Addendum Exchange Warrants Pursuant to the Series B Private Placement and the Series B Purchase Agreement, for purposes of complying with Nasdaq Listing Rule 5635(c) and 5635(d), the Company is required to hold a meeting of its stockholders not later than 60 days following the Series B Closing Date to seek approval (the “ Stockholder Approval The Company prepaid the outstanding balance of $25,000 aggregate principal amount of Promissory Notes, together with accrued and unpaid interest thereon through such prepayment date, held by a partial non-participating holder in the Exchange, following which no Promissory Notes remained outstanding. As of June 30, 2020, the Company incurred $192,071 of deferred offering costs in connection with the Series B Private Placement. In connection with the Series B Private Placement, the Company paid the placement agent 9.0% of the gross cash proceeds received by the Company from investors introduced by the placement agent and 4.0% of the gross cash proceeds received by the Company for all other investors, or approximately $1.3 million. The Company also paid the placement agent a non-accountable cash fee equal to 1.0% of the gross cash proceeds and a cash financial advisory fee equal to 3.0% of the outstanding principal balance of the Promissory Notes that were submitted in the Exchange, or approximately $0.3 million in additional cash fees in the aggregate. In addition, the Company issued to the placement agent warrants to purchase up to 1,377,458 shares of Common Stock (the “ July Placement Agent Warrants Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard On May 27, 2020, in connection with discussions with t he Listing Qualifications Department (the “ Staff Nasdaq Borkowski Note Board Note Amendment On June 11, 2020, the Company received a letter ( June Letter from the Staff providing notice that the Staff determined the Company had failed to comply with Nasdaq Listing Rule 5635(c) and Nasdaq Listing Rule 5635(d). Nasdaq Listing Rule 5635(d) requires shareholder approval for certain transactions, other than public offerings, involving the issuance of 20% or more of the total pre-transaction shares outstanding at less than the applicable Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)). The Staff’s determination under Nasdaq Listing Rule 5635(d) related to the issuance by the Company, in certain closings of a private offering between December 24, 2019 and January 9, 2020 (the “ Below Market Closings Warrants As determined by the Company in the course of its discussions with Nasdaq, the conversion price of the Convertible Notes and, for certain Below Market Closings, the exercise price of the Warrants was less than the applicable Minimum Price as of the applicable closing date. As a result, as required to be calculated under Nasdaq Listing Rule 5635(d), the aggregate potential issuance of Common Stock in the Below Market Closings inadvertently exceeded 20% of the total pre-transaction shares outstanding. As described in the June Letter, the Staff determined that it is appropriate for these purposes to aggregate shares potentially issuable in the Below Market Closings with shares potentially issuable under the equity line of credit purchase agreement (the “ Equity Line Agreement Lincoln Park Accordingly, the Staff determined, shareholder approval was required to be obtained but was not obtained under Nasdaq Listing Rule 5635(d), for both the Below Market Closings and the Equity Line Agreement. The June Letter also addressed the Company's failure to comply with Listing Rule 5635(c), which had already been remediated pursuant to the Note Amendment. Under Nasdaq Listing Rule 5810(c)(2)(C), the Company had 45 calendar days from June 11, 2020, or through Monday, July 27, 2020, to submit to Nasdaq a plan to regain compliance with Nasdaq Listing Rule 5635(d). On July 23, 2020, the Company received a letter (the “ July Letter As part of its remediation discussions with the Staff, the Company has clarified that, as of July 23, 2020, it may not issue more than 2,118,389 additional shares of Common Stock pursuant to its Equity Line Agreement with Lincoln Park without first obtaining stockholder approval, unless the average price of all applicable sales thereunder exceeds $0.70 per share calculated by reference to the “Minimum Price” under Nasdaq Listing Rule 5635(d). Basis of Presentation and Principles of Consolidation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ U.S. GAAP (“SEC” The unaudited interim consolidated financial statements include the accounts of AzurRx and its wholly-owned subsidiary, AzurRx SAS. Intercompany transactions and balances have been eliminated upon consolidation. Going Concern Uncertainty The accompanying unaudited interim consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception, had negative working capital at June 30, 2020 of approximately $6.0 million, and had an accumulated deficit of approximately $72.7 million at June 30, 2020. Subsequent to June 30, 2020, the Company raised aggregate gross proceeds of approximately $15.2 million and aggregate net proceeds of approximately $13.5 million in the Series B Private Placement. The Company is dependent on obtaining, and continues to pursue, additional working capital funding from the sale of securities and debt in order to continue to execute its development plan and continue operations. Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our primary sources of liquidity come from capital raises through additional equity and/or debt financings. This may be impacted by the novel coronavirus (“ COVID-19

Significant Accounting Policies

Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Significant Accounting Policies and Recent Accounting Pronouncements	Use of Estimates The accompanying unaudited consolidated financial statements are prepared in conformity with U.S. GAAP and include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements (including goodwill, intangible assets and contingent consideration), and the reported amounts of revenues and expenses during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid at June 30, 2020 and December 31, 2019, respectively. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At June 30, 2020 and December 31, 2019, the Company had $0 and $0, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and cash equivalents with high quality financial institutions. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method. Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. Fair Value Measurements The Company follows Accounting Standards Codification (“ASC” (“ASC 820” As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation For foreign subsidiaries with operations denominated in a foreign currency, assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through June 30, 2020. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years In Process Research & Development 12 years License Agreements 5 years Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment (“ASC 360” Income Taxes Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ASC 740” The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At June 30, 2020 and December 31, 2019, the Company does not have any significant uncertain tax positions. All tax years are still open for audit. Leases Effective January 1, 2019, the Company adopted Accounting Standards Update ( “ASU” Research and Development Research and development (“ R&D Stock-Based Compensation The Board and stockholders have adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan which took effect on May 12, 2014. The Company accounts for its stock-based compensation awards to employees and Board members in accordance with ASC Topic 718, Compensation—Stock Compensation (“ ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Sublicense Agreement As more fully discussed in Note 14, the Company entered into a sublicense agreement with TransChem, Inc. (“ TransChem Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively and is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. This ASU, which the Company adopted as of January 1, 2020, did not have a material effect on the Company’s consolidated financial statements.

Fair Value Disclosures

Fair Value Disclosures	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company's financial instruments are as follows: Fair Value Measured a Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2020: Cash $ 984,950 $ - $ 984,950 $ - $ 984,950 Other receivables $ 102,601 $ - $ - $ 102,601 $ 102,601 Note payable $ 112,609 $ - $ - $ 112,609 $ 112,609 Convertible debt $ 5,285,340 $ - $ - $ 5,285,340 $ 5,285,340 At December 31, 2019: Cash $ 175,796 $ - $ 175,796 $ - $ 175,796 Other receivables $ 2,637,303 $ - $ - $ 2,637,303 $ 2,637,303 Note payable $ 444,364 $ - $ - $ 444,364 $ 444,364 Convertible debt $ 1,076,938 $ - $ - $ 1,076,938 $ 1,076,938 At June 30, 2020, the fair value of other receivables approximates carrying value as these consist primarily of French R&D tax credits and accounts receivable that are normally received the following year. At December 31, 2019, the fair value of other receivables approximates carrying value as these consist primarily of French R&D tax credits that are normally received the following year. The fair value of the note payable in connection with the financing of directors and officer’s liability insurance approximates carrying value due to the terms of such instruments and applicable interest rates. The convertible debt is based on its fair value less unamortized debt discount plus accrued interest through the date of reporting (see Note 9).

Other Receivables

Other Receivables	6 Months Ended
	Jun. 30, 2020
Receivables [Abstract]
Other Receivables	Other receivables consisted of the following: June 30, December 31, 2020 2019 R&D tax credits $ 8,252 $ 2,566,281 Accounts receivable 36,764 - Other 57,585 71,022 Total other receivables $ 102,601 $ 2,637,303 At June 30, 2020, the R&D tax credits were comprised of a portion of the 2019 refundable tax credits for research conducted in France. At December 31, 2019, the R&D tax credits were comprised of the 2017, 2018, and 2019 refundable tax credits for research conducted in France. In the six months ended June 30, 2020, the Company received both the 2017 and 2018 and partial 2019 refundable tax credits totaling approximately $2,289,096. At December 31, 2019, Other consisted of amounts due from U.S. R&D tax credits.

Property, Equipment, and Leaseh

Property, Equipment, and Leasehold Improvements	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Equipment, and Leasehold Improvements	Property, equipment and leasehold improvements consisted of the following: June 30, December 31, 2020 2019 Laboratory equipment $ 193,661 $ 193,661 Computer equipment 77,850 74,836 Office equipment 36,703 36,703 Leasehold improvements 29,163 35,711 Total property, plant and equipment 337,377 340,911 Less accumulated depreciation (275,323 ) (263,520 ) Property, plant and equipment, net $ 62,054 $ 77,391 Depreciation expense for the three months ended June 30, 2020 and 2019 was $8,708 and $16,927, respectively. Depreciation expense for the six months ended June 30, 2020 and 2019 was $18,369 and $34,041, respectively. For the three months ended June 30, 2020, $4,720 of depreciation is included in R&D expense and $3,988 of depreciation is included in G&A expense. For the six months ended June 30, 2020, $9,491 of depreciation is included in R&D expense and $8,877 of depreciation is included in G&A expense. For the three months ended June 30, 2019, $11,751 of depreciation has been reclassified to R&D expense and $5,176 of depreciation remains in G&A expense. For the six months ended June 30, 2019, $23,846 of depreciation is included in R&D expense and $10,195 of depreciation is included in G&A expense.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Patents Pursuant to the Mayoly APA entered into on March 27, 2019, in which the Company purchased all rights, title and interest in and to MS1819 (see Note 14), the Company recorded Patents in the amount of $3,802,745 as follows: Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at 12/31/19 - €400,000 449,280 Due to Mayoly at 12/31/20 - €350,000 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745 Intangible assets are as follows: June 30, December 31, 2020 2019 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (659,435 ) (395,661 ) Patents, net $ 3,143,310 $ 3,407,084 Amortization expense for the three months ended June 30, 2020 and 2019 was $131,887 and $(131,887), respectively. Amortization expense for the six months ended June 30, 2020 and 2019 was $263,774 and $693,176, respectively. Amortization expense for the three and six months ended March 31, 2019 included $384,234, and $384,234, respectively, from In process research and development and License agreements written off as a result of the Mayoly APA. As of June 30, 2020, amortization expense related to patents is expected to be as follows for the next five years (2020 through 2025): 2020 (balance of year) $ 263,774 2021 527,548 2022 527,548 2023 527,548 2024 527,548 2025 527,548 Goodwill is as follows: Goodwill Balance at January 1, 2019 $ 1,924,830 Foreign currency translation (38,144 ) Balance at December 31, 2019 1,886,686 Foreign currency translation (3,193 ) Balance at June 30, 2020 $ 1,889,879

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: June 30, December 31, 2020 2019 Trade payables $ 1,200,341 $ 1,683,505 Accrued expenses 113,935 71,177 Total accounts payable and accrued expenses $ 1,314,281 $ 1,754,682 At June 30, 2020, and December 31, 2019, trade payables included $358,400, and $358,400, respectively, due to related parties (See Note 18).

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes Payable [Abstract]
Notes Payable	Directors and Officer’s Liability Insurance On December 5, 2019, the Company entered into a 9-month financing agreement for its directors and officer’s liability insurance in the amount of $498,783 that bears interest at an annual rate of 5.461%. Monthly payments, including principal and interest, are $56,689 per month. The balance due under this financing agreement at June 30, 2020 was $112,609. CARES ACT PPP Loan In April 2020, the Company applied for and received a CARES Act Paycheck Protection Program (“PPP”) loan of $179,418 through the Small Business Administration (SBA). In May 2020, the Company returned the loan of $179,418 after analysis of the updated guidance from the U.S. Department of Treasury and the SBA regarding the eligibility of such loans.

Convertible Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Convertible Notes	ADEC Notes On February 14, 2019, the Company entered into a Note Purchase Agreement (the “ADEC NPA” “ADEC” “Note A” “Note B,” “ADEC Note,” “ADEC Notes” ADEC Note Offering The ADEC Notes accrued interest at a rate of 10% per annum; provided, however, that in the event the Company should elect to repay the full balance due under the terms of both ADEC Notes prior to December 31, 2019, then the interest rate would be reduced to 6% per annum. Interest would be payable at the time all outstanding principal amounts owed under each ADEC Note were repaid. The ADEC Notes were scheduled to mature on the earlier to occur of (i) the tenth business day following the receipt by ABS of certain tax credits that the Company expects to receive prior to July 2019 in the case of Note A (the “2019 Tax Credit” “2020 Tax Credit” “Maturity Dates” Each of the ADEC Notes was convertible, at ADEC’s option, into shares of Common Stock, at a conversion price equal to $2.50 per share; provided, however, that pursuant to the term of the ADEC Notes, ADEC could not convert all or a portion of the ADEC Notes if such conversion would result in the significant stockholder and/or entities affiliated with him beneficially owning in excess of 19.99% of the shares of Common Stock issued and outstanding immediately after giving effect to the issuance of the shares issuable upon conversion of the ADEC Notes (the “ ADEC Note Conversion Shares As additional consideration for entering into the ADEC NPA, the Company entered into a warrant amendment agreement, whereby the Company agreed to reduce the exercise price of 1,009,565 outstanding warrants previously issued by the Company to ADEC and its affiliates (the “ADEC Warrants” ADEC Warrant Amendment In December 2019, the Company repaid $1,550,000 principal amount of the ADEC Notes and on January 2, 2020 repaid the remaining principal balance of $450,000 plus outstanding accrued interest of $104,153. As of June 30, 2020, no ADEC Notes were outstanding. Senior Convertible Promissory Note Offering On December 20, 2019, the Company began an offering of (i) Senior Convertible Promissory Notes (each a “ Promissory Note Promissory Notes Note Investors Note Warrants Promissory Promissory Note Offering In December 2019, the Company issued Promissory Notes to the Note Investors in the aggregate principal amount of $3,386,300. The Promissory Notes were scheduled to mature on September 20, 2020, accrue interest at a rate of 9% per annum, and were convertible, at the sole option of the holder, into shares of Common Stock (the “ Promissory Note Conversion Shares Conversion Option Prepayment Option On January 2, 2020, January 3, 2020, and January 9, 2020, the Company issued Promissory Notes to the Note Investors in the aggregate principal amount of $3,517,700. As additional consideration for the execution of the Promissory NPA, each Note Investor also received Note Warrants to purchase that number of shares of Common Stock equal to one-half (50%) of the Promissory Note Conversion Shares issuable upon conversion of the Promissory Notes (the “ Note Warrant Shares RRA In connection with the four closings in December 2019 of the Promissory January Placement Agent Warrants In connection with the three closings in January 2020 of the Promissory The Company determined the Prepayment Option feature represents a contingent call option. The Company evaluated the Prepayment Option in accordance with ASC 815-15-25. The Company determined that the Prepayment Option feature is clearly and closely related to the debt host instrument and is not an embedded derivative requiring bifurcation. Additionally, the Company determined the Conversion Option represents an embedded call option. The Company evaluated the Conversion Option in accordance with ASC 815-15-25. The Company determined that the Conversion Option feature meets the scope exception from ASC 815 and is not an embedded derivative requiring bifurcation. The Company evaluated the Promissory Notes for a beneficial conversion feature in accordance with ASC 470-20. The Company determined that at each commitment date the effective conversion price was below the closing stock price (market value), and the Convertible Notes contained a beneficial conversion feature. Pursuant to the December 2019 closings of the Promissory Note Offering, the principal amount of $3,386,300 was first allocated based on the relative fair value of the Promissory Notes and the Note Warrants. The fair value of the Note Warrants amounted to $912,648. Then the beneficial conversion feature was calculated, which amounted to $1,359,284. The Company incurred debt issuance costs of $588,017 related to the offering. The initial carrying value of the Promissory Notes issued amounted to $526,351. Pursuant to the January 2020 closings of the Promissory Note Offering, the principal amount of $3,517,700 was first allocated based on the relative fair value of the Promissory Notes and the Note Warrants. The fair value of the Note Warrants amounted to $2,439,272. Then the beneficial conversion feature was calculated, which amounted to $1,838,422. The Company incurred debt issuance costs of $472,326 related to the offering. The initial carrying value of the Promissory Notes issued amounted to $128,524. On June 1, 2020, the Company entered into an amendment to a certain Promissory Note in the principal amount of $100,000 issued on December 20, 2019 to Edward J. Borkowski, the chairman of the Board, to increase the Conversion Price to $1.07 per share (the “ Note Amendment During the three months ended June 30, 2020, the Company recognized $2,299,011 of interest expense related to these Promissory Notes, including amortization of debt discount related to the value of the Note Warrants of $683,437, amortization of the beneficial conversion feature of $1,100,843, amortization of debt discount related to debt issuance costs of $359,817, and accrued interest expense of $154,914. During the six months ended June 30, 2020, the Company recognized $4,508,174 of interest expense related to these Promissory Notes, including amortization of debt discount related to the value of the Note Warrants of $1,341,563, amortization of the beneficial conversion feature of $2,154,209, amortization of debt discount related to debt issuance costs of $707,411, and accrued interest expense of $304,992. Subsequent to June 30, 2020, in connection with the Series B Private Placement (See Note 1), 937.004177 shares of Series B Preferred Stock and Series B Warrants to purchase 4,684,991 shares of Common Stock were issued to certain holders of the Promissory Notes in exchange for such Promissory Notes for consideration of approximately $7.2 million aggregate outstanding principal amount, together with accrued and unpaid interest thereon through the date of the Series B Private Placement of $0.3 million. The Company prepaid the outstanding balance of $25,000 aggregate principal amount of Promissory Notes, together with accrued and unpaid interest thereon through the prepayment date, held by those holders who did not participate in the Exchange. Following these transactions, no Promissory Notes remain outstanding. Convertible Debt consisted of: Total Promissory Notes ADEC Notes Total June 30, June 30, June 30, December 31, 2020 2020 2020 2019 Convertible debt $ 6,904,000 $ 6,904,000 $ - $ 3,836,300 Unamortized debt discount - revalued warrants - - - (118,356 ) Unamortized debt discount - warrants (615,844 ) (615,844 ) - (878,979 ) Unamortized debt discount - BCF (991,968 ) (991,968 ) - (1,307,755 ) Unamortized debt discount - debt issuance costs (324,231 ) (324,231 ) - (566,815 ) Accrued interest 313,382 313,382 - 112,543 Total convertible debt $ 5,285,340 $ 5,285,340 $ - $ 1,076,938

Other Liabilities

Other Liabilities	6 Months Ended
	Jun. 30, 2020
Other Liabilities [Abstract]
Other Liabilities	Other liabilities consisted of the following: June 30, December 31, Current 2020 2019 Due to Mayoly $ 393,635 $ 392,989 Lease liabilities 87,194 83,235 Other liabilities 25,697 - $ 506,526 $ 476,224 June 30, December 31, Long-term 2020 2019 Lease liabilities 43,629 - $ 43,629 $ -

Equity

Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Equity	Our certificate of incorporation, as amended and restated on December 20, 2019 (the “ Charter On December 19, 2019, the Company held its Annual Meeting of Stockholders (the “ 2019 Annual Meeting Reverse Split Common Stock The Company had 28,502,850 and 26,800,519 shares of its Common Stock issued and outstanding at June 30, 2020 and December 31, 2019, respectively. Each holder of Common Stock is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of the stockholders. Our Charter and Amended and Restated Bylaws (the “ Bylaws In addition, the holders of our Common Stock will be entitled to receive ratably such dividends, if any, as may be declared by the Board out of legally available funds; however, the current policy of our Board is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our Common Stock will be entitled to share ratably in all assets that are legally available for distribution. Holders of our Common Stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. Preferred Stock We have 10,000,000 shares of preferred stock, par value $0.0001 per share, authorized and available for issuance in one or more series. The Board is authorized to divide the preferred stock into any number of series, fix the designation and number of each such series, and determine or change the designation, relative rights, preferences, and limitations of any series of preferred stock. The Board of may increase or decrease the number of shares initially fixed for any series, but no decrease may reduce the number below the shares then outstanding and duly reserved for issuance. As of June 30, 2020, no series of preferred stock were issued and outstanding. On July 16, 2020, we authorized 5,194.805195 shares as Series B Preferred Stock and issued 2,912.583005 shares of Series B Preferred Stock (See Note 1), with 2,282.222190 shares of Series B Preferred Stock remaining authorized but unissued. Following such transactions, we currently have 2,912.583005 shares of preferred stock issued and outstanding with 9,997,087.416995 shares of preferred stock remaining authorized but unissued. 2014 Equity Incentive Plan The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “ 2014 Plan As Converted Shares The Company issued an aggregate of 795,006 and 0 stock options, during the six months ended June 30, 2020 and 2019, respectively, under the 2014 Plan (see Note 13). As of June 30, 2020, there were an aggregate of 4,367,806 total shares available under the 2014 Plan, of which 2,272,506 are issued and outstanding, 387,000 shares are reserved subject to issuance of restricted stock and RSUs and 1,708,300 shares are available for potential issuances. The Company may issue securities outside of the 2014 Plan. Equity Line with Lincoln Park On November 13, 2019, the Company entered into a purchase agreement (the “ Equity Line Agreement Lincoln Park Registration Rights Agreement Equity Line Commitment Shares Under the Equity Line Agreement, on any business day over the term of the Equity Line Agreement, the Company has the right, in its sole discretion, to present Lincoln Park with a purchase notice (each, a “ Purchase Notice Regular Purchase Purchase Price ● the lowest sale price of Common Stock on the purchase date; and; ● the average of the three lowest closing sale prices for the Common Stock during the ten consecutive business days ending on the business day immediately preceding the purchase date of such shares; In addition, on any date on which the Company submits a Purchase Notice to Lincoln Park, the Company also has the right, in its sole discretion, to present Lincoln Park with an accelerated purchase notice (each, an “ Accelerated Purchase Notice Accelerated Purchase Accelerated Purchase Measurement Period ● 97% of the volume weighted average price of the Company’s common stock during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date; and ● the closing sale price of Common Stock on the applicable Accelerated Purchase Date. The Company may also direct Lincoln Park on any business day on which an Accelerated Purchase has been completed and all of the shares to be purchased thereunder have been properly delivered to Lincoln Park in accordance with the Equity Line Agreement, to purchase an amount of stock (the “ Additional Accelerated Purchase Additional Accelerated Purchase Measurement Period ● 97% of the volume weighted average price of the Company’s common stock during the applicable Additional Accelerated Purchase Measurement Period on the applicable Additional Accelerated Purchase date; and ● the closing sale price of Common Stock on the applicable Additional Accelerated Purchase. During the six months ended June 30, 2020, the Company issued an aggregate of 1,495,199 shares of Common Stock in connection with the Equity Line Agreement, resulting in net proceeds to the Company of approximately $988,348. Pursuant to the terms of the Equity Line Agreement, without first obtaining stockholder approval, the aggregate number of shares that the Company is permitted to sell to Lincoln Park thereunder, when aggregated with certain other private offerings of Common Stock, as applicable, may not exceed 19.99% of the Common Stock outstanding immediately prior to the execution of the Equity Line Agreement on November 13, 2019, unless the average price of all applicable sales thereunder exceeds $0.70 per share calculated by reference to the “Minimum Price” under Nasdaq Listing Rule 5635(d). As part of its discussions with the Staff of Nasdaq relating to certain remediation actions described in Note 1, the Company has clarified that, as of July 23, 2020, 2,118,389 additional shares of Common Stock remained available to be sold below such thresholds. Common Stock Issuances During the three months ended June 30, 2020, the Company did not issue any shares of its Common Stock to consultants or outside Board members. During the six months ended June 30, 2020, the Company issued an aggregate of 101,195 shares of its Common Stock to consultants with a total grant date fair value of approximately $87,105 for services provided, that was recorded was recorded as stock-based compensation, included as part of general and administrative expense. During the six months ended June 30, 2020, the Company issued an aggregate of 105,937 shares of its Common Stock to outside Board members as payment of Board fees with an aggregate grant date fair value of approximately $131,137 that was recorded as stock-based compensation, included as part of general and administrative expense. The aggregate effective settlement price was $1.24 per share, and each individual stock issuance was based on the closing stock price of the Common Stock on the initial date the payable was accrued. During the three and six months ended June 30, 2019, the Company issued 13,379 and 40,481 shares of Common Stock, respectively, to an investor relations consultant as payment of $30,000 and $90,000, respectively, of accounts payable. During the three and six months ended June 30, 2019, the Company issued an aggregate of 30,000 and 60,000 shares of its Common Stock, respectively, to outside Board members as payment of Board fees with an aggregate grant date fair value of approximately $51,000 and $123,000, respectively that was recorded as stock-based compensation, included as part of general and administrative expense. During the period from April 6, 2020 through May 22, 2020, the Company sold an aggregate of 1,345,199 shares of Common Stock pursuant to the Equity Line, from which the Company derived approximately $869,000 in net proceeds. The sales of these shares were exempt from registration under the Securities Act of 1933, as amended, in reliance upon Section 4(a)(2) (or Regulation D promulgated thereunder). Restricted Stock and Restricted Stock Units Restricted stock refers to shares of Common Stock subject to vesting based on certain service, performance, and market conditions. Restricted stock unit awards (“ RSUs During the three months ended June 30, 2020, an aggregate of 2,917 unvested restricted shares of Common Stock, subject to service conditions, vested with a total grant date fair value of approximately $10,500 and was recorded as stock-based compensation, included as part of general and administrative expense. During the six months ended June 30, 2020, an aggregate of 8,334 unvested restricted shares of Common Stock, subject to service conditions, vested with a total grant date fair value of approximately $30,008 and was recorded as stock-based compensation, included as part of general and administrative expense. During the three and six months ended June 30, 2020, an aggregate of 4,000 unvested restricted shares of Common Stock were forfeited. During the three months ended June 30, 2019, an aggregate of 47,084 unvested restricted shares of Common Stock vested with a total grant date fair value of approximately $146,169. 33,334 of these restricted shares with a total grant date fair value of approximately $101,335 vested during the three months ended June 30, 2019 due to the Company achieving certain clinical milestones. 13,750 of these restricted shares with a total grant date fair value of approximately $44,834 vested during the three months ended June 30, 2019 due to the satisfacation of service conditions. During the six months ended June 30, 2019, an aggregate of 119,667 unvested restricted shares of Common Stock vested with a total grant date fair value of approximately $369,854. 92,167 of these restricted shares with a total grant date fair value of approximately $280,188 vested during the six months ended June 30, 2019 due to the Company achieving certain clinical milestones. 27,500 of these restricted shares with a total grant date fair value of approximately $89,666 vested during the six months ended June 30, 2019 due to the satisfaction of service conditions. As of June 30, 2020, the Company had unrecognized restricted common stock expense of approximately $399,531. Approximately $6,281 of this unrecognized expense will be recognized over the average remaining vesting term of 0.15 years. Approximately $196,625 of this unrecognized expense vests upon the first commercial sale in the United States of MS1819 and approximately $196,625 of this unrecognized expense vests upon the total market capitalization of the Company exceeding $1.0 billion for 20 consecutive trading days. These milestones were not considered probable at June 30, 2020. As of June 30, 2019, the Company had unrecognized restricted common stock expense of approximately $292,359 that will be recognized over the average remaining vesting term of 1.80 years. 80 years.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2020
WarrantsDisclosureTextBlock
Warrants	For the six months ended June 30, 2020, in connection with the January 2020 closings of the Promissory Note Offering, the Company issued Note Warrants to investors to purchase an aggregate of 1,813,257 shares of Common Stock with the issuance of the Promissory Notes as referenced in Note 9. These Note Warrants were issued between January 2, 2020 and January 9, 2020, are exercisable commencing six (6) months following the issuance date at $1.07 per share and expire five years from issuance. The total grant date fair value of these warrants was determined to be approximately $1,574,886, as calculated using the Black-Scholes model, and were recorded as a debt discount based on their relative fair value. For the six months ended June 30, 2020, in connection with the January 2020 closings of the Promissory Note Offering, the Company issued placement agent warrants to purchase an aggregate of 199,732 shares of Common Stock. These placement agent warrants were issued between January 2, 2020 and January 9, 2020, vested immediately, and expire five years from issuance. 41,495 of these Placement Agent Warrants are exercisable at $1.21 per share and 158,237 are exercisable at $1.42 per share. The total grant date fair value of these placement agent warrants was determined to be approximately $174,130, as calculated using the Black-Scholes model, and was charged to debt discount that will be amortized over the life of the debt. During the six months ended June 30, 2020, warrants to purchase an aggregate of 30,096 shares of Common Stock expired with exercise prices ranging between $4.76 and $7.37 per share. Warrant transactions for the six months ended June 30, 2020 and 2019 were as follows: Exercise Weighted Price Per Average Warrants Share Exercise Price Warrants outstanding and exercisable at January 1, 2019 3,112,715 $ 2.55 - 7.37 $ 4.83 Granted during the period 75,663 $ 2.55 – 2.82 $ 2.68 Expired during the period - - - Exercised during the period - - - Warrants outstanding and exercisable at June 30, 2019 3,188,378 $ 1.50 - 7.37 $ 3.51 Warrants outstanding and exercisable at January 1, 2020 5,378,288 $ 1.07 - 7.37 $ 2.53 Granted during the period 2,012,989 $ 1.07 - 1.42 $ 1.10 Expired during the period (30,096 ) $ 4.76 - 7.37 $ 4.92 Exercised during the period - - - Warrants outstanding and exercisable at June 30, 2020 7,361,181 $ 1.07 - 7.37 $ 2.13 Number of Weighted Average Weighted Shares Under Remaining Contract Average Exercise Price Warrants Life in Years Exercise Price $ 1.07 - $1.99 4,202,899 4.48 $ 2.00 - $2.99 1,292,813 1.74 $ 3.00 - $3.99 623,787 3.20 $ 4.00 - $4.99 214,256 4.09 $ 5.00 - $5.99 551,835 5.47 $ 6.00 - $6.99 416,657 5.92 $ 7.0 0 - $7.37 58,934 3.33 Total 7,631,181 3.28 $2.13 The weighted average fair value of warrants granted during the six months ended June 30, 2020 was $1.10 per share. The fair value was estimated on the grant dates using the Black-Scholes option-pricing model with the following weighted average assumptions: June 30, 2020 Expected life (in years) 5 Volatility 81.9 % Risk-free interest rate 1.64 % Dividend yield - %

Stock Options

Stock Options	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock Options	Under the 2014 Plan, the fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the common stock price and the assumed risk-free interest rate. The Company recognizes stock-based compensation expense for only those shares expected to vest over the requisite service period of the award. No compensation cost is recorded for options that do not vest and the compensation cost from vested options, whether forfeited or not, is not reversed. During the three months ended June 30, 2020, the Company issued stock options to purchase an aggregate of 460,000 shares of Common Stock with a strike price of $0.97 per share and a term of ten years to its non-executive directors. These options had a total grant date fair value of approximately $210,284, as calculated using the Black-Scholes model. During the six months ended June 30, 2020, the Company issued additional stock options to purchase an aggregate of 335,006 shares of Common Stock with a strike price of $1.03 per share and a term of ten years to its chief financial officer that vest quarterly over three years. These options had a total grant date fair value of approximately $281,405, as calculated using the Black-Scholes model. During the three months ended June 30, 2020, stock options to purchase an aggregate of 185,000 shares of Common Stock were cancelled with strike prices ranging between $0.97 and $3.60 per share. During the six months ended June 30, 2020, stock options to purchase an aggregate of 200,000 shares of Common Stock were cancelled with strike prices ranging between $0.97 and $3.60 per share. During the three months ended June 30, 2020, stock options to purchase an aggregate of 257,917 shares of Common Stock, subject to service conditions, vested with a total grant date fair value of approximately $146,026 and were recorded as stock-based compensation, and included as part of general and administrative expense. During the six months ended June 30, 2020, stock options to purchase an aggregate of 315,834 shares of Common Stock, subject to service conditions, vested with a total grant date fair value of approximately $200,977 and were recorded as stock-based compensation, and included as part of general and administrative expense. During the three and six months ended June 30, 2020, stock options to purchase an aggregate of 50,000 shares of Common Stock, subject to performance conditions vesting, vested with a total grant date fair value of approximately $20,150 and were recorded as stock-based compensation, and included as part of general and administrative expense due to the Company determining the probability of initiating the Option 2 Clinical Trial was greater than 75% at June 30, 2020. During the three and six months ended June 30, 2019, stock options to purchase an aggregate of 893,500 shares of Common Stock were granted with an exercise price of $1.75 and a term of five years. During the three months ended June 30, 2019, no options vested. During the six months ended June 30, 2019, stock options to purchase an aggregate 244,500 shares of Common Stock vested with a total grant date fair value of approximately $511,335. stock options to purchase an aggregate 242,000 shares of Common Stock with a total grant date fair value of approximately $501,666 vested due to the Company achieving certain clinical milestones. The fair values were estimated on the grant dates using the Black-Scholes option-pricing model with the following weighted-average assumptions: June 30, 2020 Expected life (in years) 10 Volatility 84.5 % Risk-free interest rate 0.70- 0.76 % Dividend yield - % The expected term of the options is based on expected future employee exercise behavior. Volatility is based on the historical volatility of the Company’s Common Stock if available or of several public entities that are similar to the Company. The Company bases volatility this way because it may not have sufficient historical transactions in its own shares on which to solely base expected volatility. The risk-free interest rate is based on the U.S. Treasury rates at the date of grant with maturity dates approximately equal to the expected term at the grant date. The Company has not historically declared any dividends and does not expect to in the future. During the six months ended June 30, 2020 and 2019, stock option activity under the 2014 Plan was as follows: Number Average Remaining Contract Intrinsic of Shares Exercise Price Life in Years Value Stock options outstanding at January 1, 2019 994,000 $ 3.58 5.42 $ - Granted during the period - - Expired during the period - - Canceled during the period - - Exercised during the period - - Stock options outstanding at June 30, 2019 994,000 $ 3.58 5.17 $ - Exercisable at June 30, 2019 749,500 $ 3.74 5.71 $ - Non-vested stock options outstanding at January 1, 2019 244,500 $ 3.05 4.53 $ - Granted during the period - - Vested during the period (244,500 ) $ 3.05 4.53 Expired during the period - - Canceled during the period - - Exercised during the period - - Non-vested stock options outstanding at June 30, 2019 - $ - - $ - Stock options outstanding at January 1, 2020 1,677,5000 $ 2.17 5.37 $ - Granted during the period 795,006 $ 1.00 10.00 $ - Expired during the period - - Canceled during the period (200,000 ) $ 2.10 3.28 $ - Exercised during the period - - Stock options outstanding at June 30, 2020 2,272,506 $ 1.86 6.52 $ - Exercisable at June 30, 2020 1,084,834 $ 2.59 5.60 $ - Non-vested stock options outstanding at January 1, 2020 883,500 $ 1.33 6.26 $ - Granted during the period 795,006 $ 1.03 10.00 $ - Vested during the period (365,834 ) $ 2.59 6.88 $ - Expired during the period - - - Canceled during the period (125,000 ) $ 2.10 2.82 $ - Exercised during the period - - - Non-vested stock options outstanding at June 30, 2020 1,187,672 $ 1.20 7.36 $ - As of June 30, 2020, the Company had unrecognized stock-based compensation expense of approximately $908,911. Approximately $326,736 of this unrecognized expense will be recognized over the average remaining vesting term of the options of 9.62 years. Approximately $440,213 of this unrecognized expense will vest upon enrollment completion of the next MS1819 Phase II clinical trial in the U.S. for CF (the OPTION 2 Trial). Approximately $41,213 of this unrecognized expense will vest upon enrollment completion of the ongoing Combination Trial in Europe. Approximately $20,150 of this unrecognized expense will vest upon trial completion of the next MS1819 Phase II clinical trial in the U.S. for CF (the OPTION 2 Trial). Approximately $40,300 of this unrecognized expense vests upon the Company initiating a Phase III clinical trial in the U.S. for MS1819. Approximately $40,300 of this unrecognized expense vests upon initiating a U.S. Phase I clinical trial for any product other than MS1819. The Company will recognize the expense related to these milestones when the milestones become probable.

Agreements

Agreements	6 Months Ended
	Jun. 30, 2020
Agreements
Agreements	Mayoly Agreement On March 27, 2019, the Company and Laboratories Mayoly Spinder (“ Mayoly Mayoly APA JDLA During the three and six months ended June 30, 2019, the Company charged $0 and $403,020, respectively, to Mayoly under the JDLA that was in effect during both periods. TransChem Sublicense On August 7, 2017, the Company and TransChem entered into the TransChem Sublicense Agreement pursuant to which TransChem granted to us an exclusive license to certain patents (the “TransChem Licensed Patents” On March 11, 2020, the Company provided TransChem with sixty (60) days prior written notice of its intent to terminate the TransChem Sublicense Agreement. No payments were made under this Sublicense Agreement during in the three and six months ended June 30, 2020 and 2019, respectively. Employment Agreements James Sapirstein Effective October 8, 2019, the Company entered into an employment agreement with Mr. Sapirstein to serve as its President and Chief Executive Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Mr. Sapirstein provides for a base salary of $450,000 per year. In addition to the base salary, Mr. Sapirstein is eligible to receive (i) a cash bonus of up to 40% of his base salary on an annual basis, based on certain milestones that are yet to be determined; (ii) 1% of net fees received by the Company upon entering into license agreements with any third-party with respect to any product current in development or upon the sale of all or substantially all assets of the Company; (iii) an award grant of 200,000 restricted stock units (“ RSUs In the event that Mr. Sapirstein’s employment is terminated by the Company for Cause, as defined in his employment agreement, or by Mr. Sapirstein voluntarily, then he will not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards will terminate. In the event that Mr. Sapirstein’s employment is terminated as a result of an Involuntary Termination Other than for Cause, as defined in his employment agreement, Mr. Sapirstein will be entitled to receive the following compensation: (i) severance in the form of continuation of his salary (at the base salary rate in effect at the time of termination, but prior to any reduction triggering Good Reason (as such term is defined in Mr. Sapirstein’s employment agreement) for a period of twelve months following the termination date; (ii) payment of Mr. Sapirstein’s premiums to cover COBRA for a period of twelve months following the termination date; and (iii) a prorated annual bonus. Daniel Schneiderman Effective January 2, 2020, the Company entered into an employment agreement with Mr. Schneiderman to serve as the Company’s Chief Financial Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Mr. Schneiderman provides for a base salary of $285,000 per year. In addition to the base salary, Mr. Schneiderman is eligible to receive (a) an annual milestone cash bonus based on certain milestones that will be established by the Company’s Board or the Compensation Committee, and (b) a grant of stock options to purchase 335,006 shares of common stock with an exercise price of $1.03 per share, which shall vest in three equal portions on each anniversary date of the execution of Mr. Schneiderman’s employment agreement, commencing on January 2, 2021, the first anniversary date of the agreement. Mr. Schneiderman is entitled to receive 20 days of paid vacation, participate in full employee health benefits and receive reimbursement for all reasonable expenses incurred in connection with his service to the Company. The Company may terminate Mr. Schneiderman’s employment agreement at any time, with or without Cause, as such term is defined in his employment agreement. In the event that Mr. Schneiderman’s employment is terminated by the Company for Cause, as defined in Mr. Schneiderman’s employment agreement, or by Mr. Schneiderman voluntarily, then he will not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards will terminate. If the Company terminates his employment agreement without Cause, not in connection with a Change of Control, as such term is defined in Mr. Schneiderman’s employment agreement, he will be entitled to (i) all salary owed through the date of termination; (ii) any unpaid annual milestone bonus; (iii) severance in the form of continuation of his salary for the greater of a period of six months following the termination date or the remaining term of the employment agreement; (iv) payment of premiums to cover COBRA for a period of six months following the termination date; (v) a prorated annual bonus equal to the target annual milestone bonus, if any, for the year of termination multiplied by the formula set forth in the agreement. If the Company terminates Mr. Schneiderman’s employment agreement without Cause, in connection with a Change of Control, he will be entitled to the above and immediate accelerated vesting of any unvested options or other unvested awards. Dr. James E. Pennington Effective May 28, 2018, the Company entered into an employment agreement with Dr. Pennington to serve as its Chief Medical Officer. The employment agreement with Dr. Pennington provides for a base annual salary of $250,000. In addition to his salary, Dr. Pennington is eligible to receive an annual milestone bonus, awarded at the sole discretion of the Board based on his attainment of certain financial, clinical development, and/or business milestones established annually by the Board or Compensation Committee. The Company may terminate Dr. Pennington’s employment agreement at any time, with or without Cause, as such term is defined in Dr. Pennington’s employment agreement. In the event of termination by the Company other than for Cause, Dr. Pennington is entitled to three months’ severance payable over such period. In the event of termination by the Company other than for Cause in connection with a Change of Control as such term is defined in Dr. Pennington’s employment agreement, Dr. Pennington will receive six months’ severance payable over such period.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	The Company adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective approach. Prior year financial statements were not recast under the new standard. The Company leases its office and research facilities under operating leases which are subject to various rent provisions and escalation clauses. On April 1, 2020, the Company entered into a two-year lease extension (amendment) to is Hayward, CA office. The Company determined that the lease modification did not grant an additional right of use and concluded that the modification was not a separate new lease, but rather that it should reassess and remeasure the entire modified lease on the effective date of the modification. The Company accounted for the lease amendment prospectively. The Company’s leases expire at various dates through 2022. The escalation clauses are indeterminable and considered not material and have been excluded from minimum future annual rental payments. Lease expense amounted to $40,066 and $50,655, respectively, in the three months ended June 30, 2020 and 2019. Lease expense amounted to $77,081 and $101,666, respectively, in the six months ended June 30, 2020 and 2019. The weighted-average remaining lease term and weighted-average discount rate under operating leases at June 30, 2020 are: June 30, 2020 Lease term and discount rate Weighted-average remaining lease term 1.21 years Weighted-average discount rate 6.0 % Maturities of operating lease liabilities at June 30, 2020 are as follows: 2020 $ 59,847 2021 55,420 2022 23,375 Total lease payments 138,642 Less imputed interest (7,819 ) Present value of lease liabilities $ 130,823

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	The Company is subject to taxation at the federal level in both the United States and France and at the state level in the United States. At June 30, 2020 and December 31, 2019, the Company had no tax provision for either jurisdiction. At June 30, 2020 and December 31, 2019, the Company had gross deferred tax assets of approximately $16,817,000 and $16,372,000, respectively. As the Company cannot determine that it is more likely than not that the Company will realize the benefit of the deferred tax asset, a valuation allowance of approximately $16,817,000 and $16,372,000, respectively, has been established at June 30, 2020 and December 31, 2019. The change in the valuation allowance in the six months ended June 30, 2020 and 2019 was $445,000 and $2,010,000, respectively. At June 30, 2020, the Company has gross net operating loss (“ NOL Section 382 At June 30, 2020 and December 31, 2019, the Company had approximately $21,001,000 and $19,475,000, respectively, in net operating losses which it can carryforward indefinitely to offset against future French income. At June 30, 2020 and December 31, 2019, the Company had taken no uncertain tax positions that would require disclosure under ASC 740, Accounting for Income Taxes.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Common Share	Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. At June 30, 2020, diluted net loss per share did not include the effect of 7,427,032 shares of Common Stock issuable upon the conversion of convertible debt, 7,361,181 shares of Common Stock issuable upon the exercise of outstanding warrants, 387,000 shares of Common Stock pursuant to unearned and unissued restricted stock and RSUs, and 2,272,506 shares of Common Stock issuable upon the exercise of outstanding options as their effect would be antidilutive during the periods prior to conversion. At June 30, 2019, diluted net loss per share did not include the effect of 3,188,378 shares of Common Stock issuable upon the exercise of outstanding warrants, 416,000 shares of restricted Common Stock not yet issued, and 1,887,500 shares of Common Stock issuable upon the exercise of outstanding options as their effect would be antidilutive during the periods prior to conversion.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Johan (Thijs) Spoor During the year ended December 31, 2015, the Company employed the services of JIST Consulting (“ JIST On June 29, 2019, the Company accrued an incentive bonus in the amount of $255,000 payable to Mr. Spoor. Subsequent to Mr. Spoor’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount was not owed by the Company, which determination is being challenged by Mr. Spoor. As a result of management’s determination, the Company reversed the accrual in the quarter ended December 31, 2019. All unvested shares of restricted stock and stock options subject to time and other performance-based vesting conditions have been forfeited in connection with Mr. Spoor's resignation as the Company’s President and Chief Executive Officer. Mr. Spoor also declined the right to receive 241,667 earned, but unissued shares of restricted stock on April 29, 2020 in connection with his resignation from the Board. As of June 30, 2020, management was negotiating with Mr. Spoor regarding the amounts, if any, that should be paid to Mr. Spoor relating to payments due to JIST, any bonus payable, as well as the equity awards due to Mr. Spoor. Subsequent to June 30, 2020, the parties entered into a settlement and release agreement (See Note 19). Maged Shenouda From October 1, 2016 until his appointment as the Company’s Chief Financial Officer on September 25, 2017, the Company employed the services of Maged Shenouda as a financial consultant. Included in accounts payable at June 30, 2020 and 2019 is $10,000 and $50,000, respectively, for Mr. Shenouda’s services. On November 1, 2019, Mr. Shenouda submitted his resignation as Chief Financial Officer of the Company, effective November 30, 2019. On June 29, 2019, the Company accrued an incentive bonus in the amount of $100,000 payable to Mr. Shenouda. Subsequent to Mr. Shenouda’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount should not be paid, and the Company reversed the accrual in the quarter ended December 31, 2019. Subsequent to June 30, 2020, the parties entered into a settlement and release agreement (See Note 19).

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	See Note 1 for a discussion of the Series B Private Placement and the Exchange, which was consummated on July 16, 2020. Settlement with former Officers On July 9, 2020, the Company and Johan (Thijs) Spoor, its former Chief Executive Officer, entered into a settlement and general release (the “Settlement and Release”), effective July 9, 2020 (the “ Settlement Date In connection with the Settlement and Release, on July 14, 2020 we granted Mr. Spoor warrants to purchase an aggregate of 150,000 shares of Common Stock. In addition, Mr. Spoor legally released all claims to a discretionary bonus in the amount of $255,000, which was originally accrued by the Company in June 2019 but was subsequently reversed during the quarter ended December 31, 2019, legally released all claims to $348,400 due to JIST Consulting, a company controlled by Mr. Spoor, that is reflected in the Company's accounts payable as of June 30, 2020 and the Company also paid Mr. Spoor's legal expenses in the amount of $51,200. On July 2, 2020, the Company and Maged Shenouda, its former Chief Financial Officer also entered into a settlement and general release (the “ Shenouda Settlement and Release Amendment to Incentive Plan On July 16, 2020, the Board approved an amendment to the 2014 Plan. The amendment eliminates individual grant limits under the 2014 Plan that were intended to comply with the exemption for “performance-based compensation” under Section 162(m) of the Internal Revenue Code, which section has been repealed. Option Grants On July 16, 2020, the Board authorized the grant of stock options covering a total of 2,040,000 shares of Common Stock under the 2014 Plan to certain employees, officers and directors. Such options each have an exercise price of $0.85 per share, the closing market price of the Common Stock on their date of grant. James Sapirstein, Chief Executive Officer, received options to purchase up to 1,200,000 shares of the Common Stock, 600,000 of which will vest in equal monthly installments over a term of three years commencing on the one month anniversary of the issuance date, and 600,000 of which will vest upon the achievement of certain strategic milestones specified by the Compensation Committee of the Board. Daniel Schneiderman, Chief Financial Officer, received options to purchase up to 250,000 shares of Common Stock and James E. Pennington, Chief Medical Officer, received options to purchase up to 300,000 shares of Common Stock, each vesting in equal monthly installments over a term of three years commencing on the one month anniversary of the issuance date. In addition, on July 16, 2020, the Board also approved an amended and restated option grant to Daniel Schneiderman, amending and restating a grant previously made on January 2, 2020, to reduce the amount of shares issuable upon exercise of such option to be the maximum number of shares Mr. Schneiderman was eligible to receive under the Incentive Plan on the original grant date (or 300,000 shares), due to the Incentive Plan provisions relating to the Section 162(m) limitations described above. The Board also approved the issuance of a replacement option covering the balance of shares intended to be issued at that time (or 35,006 shares). The amended and restated option has an exercise price of $1.03, the closing market price of Common Stock on January 2, 2020, which was the date of its original grant, and the replacement option has an exercise price of $0.85, the closing market price of the Common Stock on its date of grant. Both the amended and restated option and the replacement option vest over a term of three years, in 36 equal monthly installments on each monthly anniversary of January 2, 2020. Amendments to Articles of Incorporation or Bylaws On August 5, 2020, the Board approved and adopted amended and restated Bylaws (the “ 2020 Amended and Restated Bylaws

Significant Accounting Polici_2

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	The accompanying unaudited consolidated financial statements are prepared in conformity with U.S. GAAP and include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements (including goodwill, intangible assets and contingent consideration), and the reported amounts of revenues and expenses during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid at June 30, 2020 and December 31, 2019, respectively.
Concentrations of Credit Risk	Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At June 30, 2020 and December 31, 2019, the Company had $0 and $0, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and cash equivalents with high quality financial institutions. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.
Debt Instruments	Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved.
Debt Issuance Costs	Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method.
Equity-Based Payments to Non-Employees	Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting.
Fair Value Measurements	The Company follows Accounting Standards Codification (“ASC” (“ASC 820” As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Foreign Currency Translation	For foreign subsidiaries with operations denominated in a foreign currency, assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity.
Goodwill and Intangible Assets	Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through June 30, 2020. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years In Process Research & Development 12 years License Agreements 5 years
Impairment of Long-Lived Assets	The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment (“ASC 360”
Income Taxes	Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ASC 740” The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At June 30, 2020 and December 31, 2019, the Company does not have any significant uncertain tax positions. All tax years are still open for audit.
Leases	Effective January 1, 2019, the Company adopted Accounting Standards Update ( “ASU”
Research and Development	Research and development (“ R&D
Stock-Based Compensation	The Board and stockholders have adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan which took effect on May 12, 2014. The Company accounts for its stock-based compensation awards to employees and Board members in accordance with ASC Topic 718, Compensation—Stock Compensation (“ ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
Sublicense Agreement	As more fully discussed in Note 14, the Company entered into a sublicense agreement with TransChem, Inc. (“ TransChem
Subsequent Events	The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements.
Recent Accounting Pronouncements	In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively and is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. This ASU, which the Company adopted as of January 1, 2020, did not have a material effect on the Company’s consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Goodwill and intangible assets	Patents 7.2 years In Process Research & Development 12 years License Agreements 5 years

Fair Value Disclosures (Tables)

Fair Value Disclosures (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Financial instruments measured at fair value on a recurring basis	Fair Value Measured a Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2020: Cash $ 984,950 $ - $ 984,950 $ - $ 984,950 Other receivables $ 102,601 $ - $ - $ 102,601 $ 102,601 Note payable $ 112,609 $ - $ - $ 112,609 $ 112,609 Convertible debt $ 5,285,340 $ - $ - $ 5,285,340 $ 5,285,340 At December 31, 2019: Cash $ 175,796 $ - $ 175,796 $ - $ 175,796 Other receivables $ 2,637,303 $ - $ - $ 2,637,303 $ 2,637,303 Note payable $ 444,364 $ - $ - $ 444,364 $ 444,364 Convertible debt $ 1,076,938 $ - $ - $ 1,076,938 $ 1,076,938

Other Receivables (Tables)

Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2020
Receivables [Abstract]
Other receivables	June 30, December 31, 2020 2019 R&D tax credits $ 8,252 $ 2,566,281 Accounts receivable 36,764 - Other 57,585 71,022 Total other receivables $ 102,601 $ 2,637,303

Property, Equipment, and Leas_2

Property, Equipment, and Leasehold Improvements (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property, equipment and leasehold improvements	June 30, December 31, 2020 2019 Laboratory equipment $ 193,661 $ 193,661 Computer equipment 77,850 74,836 Office equipment 36,703 36,703 Leasehold improvements 29,163 35,711 Total property, plant and equipment 337,377 340,911 Less accumulated depreciation (275,323 ) (263,520 ) Property, plant and equipment, net $ 62,054 $ 77,391

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at 12/31/19 - €400,000 449,280 Due to Mayoly at 12/31/20 - €350,000 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745
Intangible assets	June 30, December 31, 2020 2019 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (659,435 ) (395,661 ) Patents, net $ 3,143,310 $ 3,407,084
Future amortization expense	2020 (balance of year) $ 263,774 2021 527,548 2022 527,548 2023 527,548 2024 527,548 2025 527,548
Goodwill	Goodwill Balance at January 1, 2019 $ 1,924,830 Foreign currency translation (38,144 ) Balance at December 31, 2019 1,886,686 Foreign currency translation (3,193 ) Balance at June 30, 2020 $ 1,889,879

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	June 30, December 31, 2020 2019 Trade payables $ 1,200,341 $ 1,683,505 Accrued expenses 113,935 71,177 Total accounts payable and accrued expenses $ 1,314,281 $ 1,754,682

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Convertible notes	Total Promissory Notes ADEC Notes Total June 30, June 30, June 30, December 31, 2020 2020 2020 2019 Convertible debt $ 6,904,000 $ 6,904,000 $ - $ 3,836,300 Unamortized debt discount - revalued warrants - - - (118,356 ) Unamortized debt discount - warrants (615,844 ) (615,844 ) - (878,979 ) Unamortized debt discount - BCF (991,968 ) (991,968 ) - (1,307,755 ) Unamortized debt discount - debt issuance costs (324,231 ) (324,231 ) - (566,815 ) Accrued interest 313,382 313,382 - 112,543 Total convertible debt $ 5,285,340 $ 5,285,340 $ - $ 1,076,938

Other Liabilities (Tables)

Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Other Liabilities [Abstract]
Other liabilities	June 30, December 31, Current 2020 2019 Due to Mayoly $ 393,635 $ 392,989 Lease liabilities 87,194 83,235 Other liabilities 25,697 - $ 506,526 $ 476,224 June 30, December 31, Long-term 2020 2019 Lease liabilities 43,629 - $ 43,629 $ -

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
WarrantsDisclosureTextBlock
Stock warrant transactions	Exercise Weighted Price Per Average Warrants Share Exercise Price Warrants outstanding and exercisable at January 1, 2019 3,112,715 $ 2.55 - 7.37 $ 4.83 Granted during the period 75,663 $ 2.55 – 2.82 $ 2.68 Expired during the period - - - Exercised during the period - - - Warrants outstanding and exercisable at June 30, 2019 3,188,378 $ 1.50 - 7.37 $ 3.51 Warrants outstanding and exercisable at January 1, 2020 5,378,288 $ 1.07 - 7.37 $ 2.53 Granted during the period 2,012,989 $ 1.07 - 1.42 $ 1.10 Expired during the period (30,096 ) $ 4.76 - 7.37 $ 4.92 Exercised during the period - - - Warrants outstanding and exercisable at June 30, 2020 7,361,181 $ 1.07 - 7.37 $ 2.13
Warrants by exercise price	Number of Weighted Average Weighted Shares Under Remaining Contract Average Exercise Price Warrants Life in Years Exercise Price $ 1.07 - $1.99 4,202,899 4.48 $ 2.00 - $2.99 1,292,813 1.74 $ 3.00 - $3.99 623,787 3.20 $ 4.00 - $4.99 214,256 4.09 $ 5.00 - $5.99 551,835 5.47 $ 6.00 - $6.99 416,657 5.92 $ 7.0 0 - $7.37 58,934 3.33 Total 7,631,181 3.28 $2.13
Share-based payment weighted average assumptions	June 30, 2020 Expected life (in years) 5 Volatility 81.9 % Risk-free interest rate 1.64 % Dividend yield - %

Stock-Based Compensation Plan (

Stock-Based Compensation Plan (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]
Share-based payment weighted average assumptions	June 30, 2020 Expected life (in years) 10 Volatility 84.5 % Risk-free interest rate 0.70- 0.76 % Dividend yield - %
Stock option activity	Number Average Remaining Contract Intrinsic of Shares Exercise Price Life in Years Value Stock options outstanding at January 1, 2019 994,000 $ 3.58 5.42 $ - Granted during the period - - Expired during the period - - Canceled during the period - - Exercised during the period - - Stock options outstanding at June 30, 2019 994,000 $ 3.58 5.17 $ - Exercisable at June 30, 2019 749,500 $ 3.74 5.71 $ - Non-vested stock options outstanding at January 1, 2019 244,500 $ 3.05 4.53 $ - Granted during the period - - Vested during the period (244,500 ) $ 3.05 4.53 Expired during the period - - Canceled during the period - - Exercised during the period - - Non-vested stock options outstanding at June 30, 2019 - $ - - $ - Stock options outstanding at January 1, 2020 1,677,5000 $ 2.17 5.37 $ - Granted during the period 795,006 $ 1.00 10.00 $ - Expired during the period - - Canceled during the period (200,000 ) $ 2.10 3.28 $ - Exercised during the period - - Stock options outstanding at June 30, 2020 2,272,506 $ 1.86 6.52 $ - Exercisable at June 30, 2020 1,084,834 $ 2.59 5.60 $ - Non-vested stock options outstanding at January 1, 2020 883,500 $ 1.33 6.26 $ - Granted during the period 795,006 $ 1.03 10.00 $ - Vested during the period (365,834 ) $ 2.59 6.88 $ - Expired during the period - - - Canceled during the period (125,000 ) $ 2.10 2.82 $ - Exercised during the period - - - Non-vested stock options outstanding at June 30, 2020 1,187,672 $ 1.20 7.36 $ -

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Operating lease information	June 30, 2020 Lease term and discount rate Weighted-average remaining lease term 1.21 years Weighted-average discount rate 6.0 %
Maturities of operating lease liabilities	2020 $ 59,847 2021 55,420 2022 23,375 Total lease payments 138,642 Less imputed interest (7,819 ) Present value of lease liabilities $ 130,823

The Company and Basis of Pres_2

The Company and Basis of Presentation (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred offering costs	$ 192,071	$ 0
Accumulated deficit	$ (72,651,900)	$ (62,694,732)

Significant Accounting Polici_4

Significant Accounting Policies and Recent Accounting Pronouncements (Details)	6 Months Ended
	Jun. 30, 2020
Patents
Useful life	7 years 2 months 12 days
In Process Research & Development
Useful life	12 years
License Agreements
Useful life	5 years

Significant Accounting Polici_5

Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash in excess of FDIC limit	$ 0	$ 0

Fair Value Disclosures (Details

Fair Value Disclosures (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Cash	$ 984,950	$ 175,796
Other receivables	102,601	2,637,303
Notes payable	112,609	444,364
Convertible debt	5,285,340	1,076,938
Level 1
Cash	0	0
Other receivables	0	0
Notes payable	0	0
Convertible debt	0	0
Level 2
Cash	984,950	175,796
Other receivables	0	0
Notes payable	0	0
Convertible debt	0	0
Level 3
Cash	0	0
Other receivables	102,601	2,637,303
Notes payable	112,609	444,364
Convertible debt	5,285,340	1,076,938
CarryingAmount [Member]
Cash	984,950	175,796
Other receivables	102,601	2,637,303
Notes payable	112,609	444,364
Convertible debt	$ 5,285,340	$ 1,076,938

Other Receivables (Details)

Other Receivables (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Receivables [Abstract]
R&D tax credits	$ 8,252	$ 2,566,281
Accounts receivable	36,764	0
Other	57,585	71,022
Other receivables	$ 102,601	$ 2,637,303

Property, Equipment, and Leas_3

Property, Equipment, and Leasehold Improvements (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, equipment and leasehold improvements, gross	$ 337,377	$ 340,911
Less accumulated depreciation	(275,323)	(263,520)
Property, equipment and leasehold improvements, net	62,054	77,391
Laboratory Equipment
Property, equipment and leasehold improvements, gross	193,661	74,836
Computer Equipment
Property, equipment and leasehold improvements, gross	77,850	36,703
Office Equipment
Property, equipment and leasehold improvements, gross	36,703	193,661
Leasehold Improvements
Property, equipment and leasehold improvements, gross	$ 29,163	$ 35,711

Property, Equipment, and Leas_4

Property, Equipment, and Leasehold Improvements (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Depreciation expense	$ 8,708	$ 16,927	$ 18,368	$ 34,041
Research and Development Expense [Member]
Depreciation expense	4,720	11,751	9,491	23,846
G&A Expense [Member]
Depreciation expense	$ 3,988	$ 5,176	$ 8,877	$ 10,195

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details)	Jun. 30, 2020USD ($)
Patents	$ 3,802,745
Common Stock Issued at Signing to Mayoly
Patents	1,740,959
Due to Mayoly at 12/31/19
Patents	449,280
Due to Mayoly at 12/31/20
Patents	393,120
Assumed Mayoly Liabilties and Forgiveness of Mayoly Debt
Patents	$ 1,219,386

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill (Details 1) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Intangible assets, gross	$ 3,802,745
Patents
Intangible assets, gross	3,802,745	$ 3,802,745
Less accumulated amortization	(659,435)	(395,661)
Intangible assets, net	$ 3,143,310	$ 3,407,804

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details 2)	Jun. 30, 2020USD ($)
Amortization expense
2020 (balance of year)	$ 263,774
2021	527,548
2022	527,548
2023	527,548
2024	527,548
2025	$ 527,548

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill (Details 3) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, beginning	$ 1,886,686	$ 1,924,830
Foreign currency translation	(3,193)	(38,144)
Goodwill, ending	$ 1,889,879	$ 1,886,686

Intangible Assets and Goodwil_6

Intangible Assets and Goodwill (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 131,887	$ 131,887	$ 263,774	$ 693,176

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Trade payables	$ 1,200,341	$ 1,683,505
Accrued expenses	113,935	71,177
Total accounts payable and accrued expenses	$ 1,314,281	$ 1,754,682

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Due to related parties	$ 358,400	$ 358,400

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Convertible debt, gross	$ 6,904,000	$ 3,836,300
Unamortized debt discount - revalued warrants	0	(118,356)
Unamortized debt discount - warrants	(615,844)	(878,979)
Unamortized debt discount - BCF	(991,968)	(1,307,755)
Unamortized debt discount - debt issuance costs	(324,231)	(566,815)
Accrued interest	313,382	112,543
Convertible debt, net	5,285,340	$ 1,076,938
Promissory Notes
Convertible debt, gross	6,904,000
Unamortized debt discount - revalued warrants	0
Unamortized debt discount - warrants	(615,844)
Unamortized debt discount - BCF	(991,968)
Unamortized debt discount - debt issuance costs	(324,231)
Accrued interest	313,382
Convertible debt, net	5,285,340
ADEC Notes
Convertible debt, gross	0
Unamortized debt discount - revalued warrants	0
Unamortized debt discount - warrants	0
Unamortized debt discount - BCF	0
Unamortized debt discount - debt issuance costs	0
Accrued interest	0
Convertible debt, net	$ 0

Other Liabilities (Details)

Other Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Other Liabilities [Abstract]
Due to Mayoly, current	$ 393,635	$ 392,989
Lease liabilities, current	87,194	83,235
Other liabilities, current	25,697	0
Total other liabilities, current	506,526	476,224
Lease liabilities, noncurrent	43,629	0
Total other liabilities, noncurrent	$ 43,629	$ 0

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jul. 16, 2020	Dec. 31, 2019
Common stock shares, issued	28,502,850		28,502,850			26,800,519
Common stock shares, outstanding	28,502,850		28,502,850			26,800,519
Preferred stock, authorized	10,000,000		10,000,000			10,000,000
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, issued	0		0
Preferred stock, outstanding	0		0
2014 Equity Incentive Plan
Shares issued pursuant to 2014 Equity Incentive Plan			795,006	0
Shares available for grant under 2014 Equity Incentive Plan	4,367,806		4,367,806
Shares issued and outstanding pursuant to 2014 Equity Incentive Plan	2,272,506		2,272,506
Equity Line
Purchase commitment			$ 15,000,000
Proceeds from sale of stock			$ 869,000
Share based compensation
Shares issued	0
Restricted stock, shares vested in period	2,917	119,667	8,334	47,084
Restricted stock, shares vested in period, value	$ 10,500	$ 369,854	$ 30,008	$ 146,169
Restricted stock, forfeitures	4,000
Unrecognized restricted common stock expense	$ 399,531	$ 292,359	$ 399,531	$ 292,359
Consultant [Member]
Share based compensation
Shares issued		13,379	101,195	40,481
Shares issued, value		$ 30,000	$ 87,105	$ 90,000
Directors [Member]
Share based compensation
Shares issued		30,000	105,937	60,000
Shares issued, value		$ 51,000	$ 131,137	$ 123,000
Commitment Shares [Member]
Equity Line
Shares issued			487,168
Tranche [Member]
Equity Line
Shares issued			1,345,199
Series B Preferred Stock [Member]
Preferred stock, authorized					5,194.805195
Preferred stock, issued					2,912.583005
Preferred stock, outstanding					2,912.583005

Warrants (Details)

Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Warrants issued and exercisable, beginning	5,378,288	3,112,715
Granted	2,012,989	75,663
Expired	(30,096)	0
Exercised	0	0
Warrants issued and exercisable, ending	7,361,181	3,188,378
Exercise price expired		$ .00
Exercise price exercised	$ .00	.00
Weighted average exercise price, beginning	2.53	4.83
Weighted average exercise price, granted	1.10	2.68
Weighted average exercise price warrants, expired	4.92	.00
Weighted average exercise price warrants, exercised	.00	.00
Weighted average exercise price, ending	2.13	3.51
Minimum
Exercise price outstanding, beginning	1.07	2.55
Exercise price granted	1.07	2.55
Exercise price expired	4.76
Exercise price outstanding, ending	1.07	1.50
Maximum
Exercise price outstanding, beginning	7.37	7.37
Exercise price granted	1.42	2.82
Exercise price expired	7.37
Exercise price outstanding, ending	$ 7.37	$ 7.37

Warrants (Details 1)

Warrants (Details 1)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of shares under warrants	7,361,181
Weighted average remaining contract life in years	3 years 3 months 11 days
Weighted average exercise price | $ / shares	$ 2.13
Warrant 1
Exercise price	$1.07 - $1.99
Number of shares under warrants	4,202,899
Weighted average remaining contract life in years	4 years 5 months 23 days
Warrant 2
Exercise price	$2.00 - $2.99
Number of shares under warrants	1,292,813
Weighted average remaining contract life in years	1 year 8 months 27 days
Warrant 3
Exercise price	$3.00 - $3.99
Number of shares under warrants	623,787
Weighted average remaining contract life in years	3 years 2 months 12 days
Warrant 4
Exercise price	$4.00 - $4.99
Number of shares under warrants	214,256
Weighted average remaining contract life in years	4 years 1 month 2 days
Warrant 5
Exercise price	$5.00 - $5.99
Number of shares under warrants	551,835
Weighted average remaining contract life in years	5 years 5 months 19 days
Warrant 6
Exercise price	$6.00 - $6.99
Number of shares under warrants	416,657
Weighted average remaining contract life in years	5 years 11 months 1 day
Warrant 7
Exercise price	$7.00 - $7.37
Number of shares under warrants	58,934
Weighted average remaining contract life in years	3 years 3 months 29 days

Warrants (Details 2)

Warrants (Details 2)	6 Months Ended
	Jun. 30, 2020
WarrantsDisclosureTextBlock
Expected life (in years)	5 years
Volatility	81.90%
Risk-free interest rate	1.64%
Dividend yield	0.00%

Stock Options (Details)

Stock Options (Details)	6 Months Ended
	Jun. 30, 2020
Expected life (in years)	5 years
Volatility	81.90%
Dividend yield	0.00%
Stock Option
Expected life (in years)	10 years
Volatility	84.50%
Risk-free interest rate, minimum	0.70%
Risk-free interest rate, maximum	0.76%
Dividend yield	0.00%

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Number of options outstanding, ending	2,272,506
Stock Option
Number of options outstanding, beginning	1,677,500	994,000
Number of options granted	795,006	0
Number of options expired	0	0
Number of options canceled	(200,000)	0
Number of options exercised	0	0
Number of options outstanding, ending	2,272,506	994,000
Number of options exercisable	1,084,834	749,500
Weighted average exercise price outstanding, beginning	$ 2.17	$ 3.58
Weighted average exercise price granted	1	0
Weighted average exercise price expired	0	0
Weighted average exercise price canceled	2.10	0
Weighted average exercise price exercised	0	0
Weighted average exercise price outstanding,ending	1.86	3.58
Weighted average exercise price exercisable	$ 2.59	$ 3.74
Weighted average remaining contract life in years, beginning	5 years 4 months 13 days	5 years 5 months 1 day
Weighted average remaining contract life in years granted	10 years
Weighted average remaining contract life in years canceled	3 years 3 months 11 days
Weighted average remaining contract life in years, ending	6 years 6 months 7 days	5 years 2 months 1 day
Weighted average remaining contract life in years exercisable	5 years 7 months 6 days	5 years 8 months 16 days
Aggregate intrinsic value outstanding, beginning	$ 0	$ 0
Aggregate intrinsic value granted	0	0
Aggregate intrinsic value expired	0	0
Aggregate intrinsic value canceled	0	0
Aggregate intrinsic value exercised	0	0
Aggregate intrinsic value outstanding, ending	0	0
Aggregate intrinsic value exercisable	$ 0	$ 0
Non-vested Stock Option
Number of options outstanding, beginning	883,500	244,500
Number of options granted	795,006	0
Number of options vested	(365,834)	(244,500)
Number of options expired	0	0
Number of options canceled	(125,000)	0
Number of options exercised	0	0
Number of options outstanding, ending	1,187,672	0
Weighted average exercise price outstanding, beginning	$ 1.33	$ 3.05
Weighted average exercise price granted	1.03	0
Weighted average exercise price vested	2.59	3.05
Weighted average exercise price expired	0	0
Weighted average exercise price canceled	2.10	0
Weighted average exercise price exercised	0	0
Weighted average exercise price outstanding,ending	$ 1.20	$ 0
Weighted average remaining contract life in years, beginning	6 years 3 months 4 days	4 years 6 months 11 days
Weighted average remaining contract life in years granted	10 years
Weighted average remaining contract life in years vested	6 years 10 months 17 days	4 years 6 months 11 days
Weighted average remaining contract life in years canceled	2 years 9 months 25 days
Weighted average remaining contract life in years, ending	7 years 4 months 10 days
Aggregate intrinsic value outstanding, beginning	$ 0	$ 0
Aggregate intrinsic value granted	0
Aggregate intrinsic value vested	0
Aggregate intrinsic value expired	0
Aggregate intrinsic value canceled	0
Aggregate intrinsic value exercised	0
Aggregate intrinsic value outstanding, ending	$ 0	$ 0

Leases (Details)

Leases (Details)	Jun. 30, 2020
Leases [Abstract]
Weighted-average remaining lease term	1 year 2 months 16 days
Weighted-average discount rate	6.00%

Leases (Details 1)

Leases (Details 1)	Jun. 30, 2020USD ($)
Leases [Abstract]
2020	$ 59,847
2021	55,420
2022	23,375
Total lease payments	138,642
Less: imputed interest	(7,819)
Present value of lease liabilities	$ 130,823

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Lease expense	$ 40,066	$ 50,655	$ 77,081	$ 101,666

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Gross deferred tax asset	$ 16,996,000		$ 16,372,000
Deferred tax asset valuation allowance	16,996,000		16,372,000
Change in valuation allowance	624,000	$ 2,010,000
Net operating loss carry-forwards	$ 21,001,000		$ 19,475,000

Net Loss per Common Share (Deta

Net Loss per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Convertible Debt
Anti-dilutive shares excluded from earnings per share	7,427,032
Warrants
Anti-dilutive shares excluded from earnings per share	7,361,181	3,188,378
Restricted stock
Anti-dilutive shares excluded from earnings per share	387,000	416,000
Stock Option
Anti-dilutive shares excluded from earnings per share	2,272,506	1,887,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounts payable	$ 1,314,281	$ 1,754,682
JIST
Accounts payable		348,400	$ 478,400
Consultant
Accounts payable		$ 10,000	$ 50,000